NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

Maglione M, Maher AR, Hu J, et al. Off-Label Use of Atypical Antipsychotics: An Update [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US); 2011 Sep. (Comparative Effectiveness Reviews, No. 43.)

Cover of Off-Label Use of Atypical Antipsychotics: An Update

Off-Label Use of Atypical Antipsychotics: An Update [Internet].

Show details

References

1.
Shekelle P, Maglione M, Bagley S, et al. Comparative Effectiveness of Off-label Uses of Atypical Antipsychotics. 2007. Available at: www​.effectivehealthcare​.ahrq.gov/ehc/products​/5/63/Atypical_Antipsychotics​_Final_Report.pdf: Prepared by the Southern California/RAND Evidence-based Practice Center under Contract No. 290-02-0003. [PubMed: 20704049]
2.
NIMH. Health Topics: Anxiety Disorders. [cited] Available at: www​.nimh.nih.gov/health​/topics/anxiety-disorders/index.shtml.
3.
Kessler RC, Chiu WT, Demler O, et al. Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry. 2005;62(6):617–27. [PMC free article: PMC2847357] [PubMed: 15939839]
4.
Hyman SE, Rudorfer MV. Anxiety Disorder. In: Dale DC, Federman DD, editors. Scientific American® Medicine. Vol. 3. New York: Healtheon/WebMD Corp.; 2000. Sect. 13, Subsect. VIII. 2000.
5.
AHAF. The Facts on Alzheimer's Disease. [January 11, 2011]. Available at: www​.ahaf.org/alzheimers​/about/understanding/facts.html.
6.
Rayner AV, OB JG, Schoenbachler B. Behavior disorders of dementia: recognition and treatment. Am Fam Physician. 2006;73(4):647–52. [PubMed: 16506707]
7.
NIMH. Health Topics: Depression. 2008. [cited] Available at: www​.nimh.nih.gov/health​/publications/depression​/complete-index.shtml.
8.
DSM-IV-TR Workgroup. The Diagnostic and Statistical Manual of Mental Disorders. 4. Washington, DC: American Psychiatric Association; 2000. Text Revision.
9.
Practice guideline for the treatment of patients with major depressive disorder (revision). American Psychiatric Association. Am J Psychiatry. 2000;157(4 Suppl):1–45. [PubMed: 10767867]
10.
Rothschild AJ. Challenges in the treatment of depression with psychotic features. Biol Psychiatry. 2003;53(8):680–90. [PubMed: 12706954]
11.
Anderson AE. Eating disorders in males: Critical questions. In: Lemberg R, editor. Controlling Eating Disorders with Facts, Advice and Resources. Phoenix, AZ: Oryx Press; 1992. pp. 20–8.
12.
Rajput V, Bromley SM. Chronic Insomnia: A Practical Review. 1999. Available at: www​.aafp.org/afp/991001ap/1431.html. [PubMed: 10524487]
13.
NIMH. Health Topics: Obsessive-Compulsive Disorder, OCD. [cited] Available at: www​.nimh.gov/health/topics​/obsessive-compulsive-disorder-ocd/index.shtml.
14.
15.
Moore DP, Jefferson JW. Schizotypal personality disorder, Handbook of Medical Psychiatry. 2. Philadelphia: Pa: Mosby Elsevier; 2004.
16.
Paris J. Recent advances in the treatment of borderline personality disorder. Can J Psychiatry. 2005;50(8):435–41. [PubMed: 16127960]
17.
Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials. 1996;17(1):1–12. [PubMed: 8721797]
18.
Moher D, Pham B, Jones A, et al. Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses? Lancet. 1998;352(9128):609–13. [PubMed: 9746022]
19.
Wells GA, Shea B, O'Connell D, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Available at: wwwohrica​/programs/clinical​_epidemiology/oxford.asp.
20.
Godwin M, Ruhland L, Casson I, et al. Pragmatic controlled clinical trials in primary care: the struggle between external and internal validity. BMC Med Res Methodol. 2003;3:28. [PMC free article: PMC317298] [PubMed: 14690550]
21.
Gartlehner G, Hansen RA, Nissman D, et al. A simple and valid tool distinguished efficacy from effectiveness studies. J Clin Epidemiol. 2006;59(10):1040–8. [PubMed: 16980143]
22.
Owens DK, Lohr KN, Atkins D, et al. Grading the strength of a body of evidence when comparing medical interventions-Agency for Healthcare Research and Quality and the Effective Health Care Program. J Clin Epidemiol. 2009 [PubMed: 19595577]
23.
Atkins D, Best D, Briss PA, et al. Grading quality of evidence and strength of recommendations. BMJ. 2004;328(7454) [PMC free article: PMC428525] [PubMed: 15205295]
24.
Hedges LV, Olkin I. Statistical Methods for Meta-Analysis. San Diego, CA: Academic Press Inc.; 1985.
25.
Cohen J. Statistical Power Analysis for the Behavioral Sciences. 2. Routledge Academic; 1988. Available at: www​.amazon.com/Statistical-Power-Analysis-Behavioral-Sciences/dp/0805802835#_.
26.
DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7(3):177–88. [PubMed: 3802833]
27.
Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994;50(4):1088–101. [PubMed: 7786990]
28.
Egger M, Davey Smith G, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315(7109):629–34. [PMC free article: PMC2127453] [PubMed: 9310563]
29.
Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557–60. [PMC free article: PMC192859] [PubMed: 12958120]
30.
StataCorp. Stata Statistical Software. 2007.
31.
Hermann RC, Yang D, Ettner SL, et al. Prescription of antipsychotic drugs by office-based physicians in the United States, 1989-1997. Psychiatr Serv. 2002;53(4):425–30. [PubMed: 11919355]
32.
Aparasu RR, Bhatara V, Gupta S. U.S. national trends in the use of antipsychotics during office visits, 1998-2002. Ann Clin Psychiatry. 2005;17(3):147–52. [PubMed: 16433056]
33.
Aparasu RR, Jano E, Bhatara V. Concomitant antipsychotic prescribing in US outpatient settings. Res Social Adm Pharm. 2009;5(3):234–41. [PubMed: 19733824]
34.
Van Brunt DL, Gibson PJ, Ramsey JL, et al. Outpatient use of major antipsychotic drugs in ambulatory care settings in the United States, 1997–2000. Med Gen Med. 2003;5:16. [PubMed: 14600653]
35.
Sankaranarayanan J, Puumala SE. Antipsychotic use at adult ambulatory care visits by patients with mental health disorders in the United States, 1996-2003: national estimates and associated factors. Clin Ther. 2007;29(4):723–41. [PubMed: 17617297]
36.
Sankaranarayanan J, Puumala SE. Epidemiology and characteristics of emergency departments visits by US adults with psychiatric disorder and antipsychotic mention from 2000 to 2004. Curr Med Res Opin. 2007;23(6):1375–85. [PubMed: 17594776]
37.
Alexander GC, Gallagher SA, Mascola A, et al. Increasing off-label use of antipsychotic medications in the United States, 1995-2008. Pharmacoepidemiol Drug Saf. 2011;20(2):177–84. [PMC free article: PMC3069498] [PubMed: 21254289]
38.
Cascade E, Kalali AH, Cummings JL. Use of atypical antipsychotics in the elderly. Psychiatry (Edgmont) 2008;5(7):28–31. [PMC free article: PMC2695730] [PubMed: 19727265]
39.
Gruber-Baldini AL, Stuart B, Zuckerman IH, et al. Treatment of dementia in community-dwelling and institutionalized Medicare beneficiaries. Journal of the American Geriatrics Society. 2007;55(10):1508–16. [PubMed: 17727648]
40.
Kamble P, Chen H, Sherer J, et al. Antipsychotic drug use among elderly nursing home residents in the United States. Am J Geriatr Pharmacother. 2008;6(4):187–97. [PubMed: 19028374]
41.
Jano E, Johnson M, Chen H, et al. Determinants of atypical antipsychotic use among antipsychotic users in community-dwelling elderly, 1996-2004. Curr Med Res Opin. 2008;24(3):709–16. [PubMed: 18226325]
42.
Polinski JM, Wang PS, Fischer MA. Medicaid's Prior Authorization Program And Access To Atypical Antipsychotic Medications. Health Aff. 2007;26(3):750–60. [PubMed: 17485754]
43.
Dorsey ER, Rabbani A, Gallagher SA, et al. Impact of FDA black box advisory on antipsychotic medication use. Arch Intern Med. 2010;170(1):96–103. [PMC free article: PMC4598075] [PubMed: 20065205]
44.
Saad M, Cassagnol M, Ahmed E. The Impact of FDA's Warning on the Use of Antipsychotics in Clinical Practice: A Survey. Consult Pharm. 2010;25(11):739–44. [PubMed: 21138822]
45.
Valiyeva E, Herrmann N, Rochon PA, et al. Effect of regulatory warnings on antipsychotic prescription rates among elderly patients with dementia: a population-based time-series analysis. CMAJ. 2008;179(5):438–46. [PMC free article: PMC2518182] [PubMed: 18725616]
46.
Olfson M, Blanco C, Liu L, et al. National Trends in the Outpatient Treatment of Children and Adolescents With Antipsychotic Drugs. Arch Gen Psychiatry. 2006;63(6):679–85. [PubMed: 16754841]
47.
Aparasu RR, Bhatara V. Patterns and determinants of antipsychotic prescribing in children and adolescents, 2003-2004. Curr Med Res Opin. 2007;23(1):49–56. [PubMed: 17257465]
48.
Cooper WO, Hickson GB, Fuchs C, et al. New users of antipsychotic medications among children enrolled in TennCare. Arch Pediatr Adolesc Med. 2004;158(8):753–9. [PubMed: 15289247]
49.
Pathak P, West D, Martin BC, et al. Evidence-based use of second-generation antipsychotics in a state Medicaid pediatric population, 2001-2005. Psychiatr Serv. 2010;61(2):123–9. [PubMed: 20123816]
50.
Halloran DR, Swindle J, Takemoto SK, et al. Multiple psychiatric diagnoses common in privately insured children on atypical antipsychotics. Clin Pediatr (Phila) 2010;49(5):485–90. [PMC free article: PMC3807865] [PubMed: 20118088]
51.
Sernyak MJ, Kosten TR, Fontana A, et al. Neuroleptic Use in the Treatment of Post-Traumatic Stress Disorder. Psychiatric Quarterly. 2001;72(3):197–213. [PubMed: 11467155]
52.
Mohamed S, Rosenheck R. Pharmacotherapy for older veterans diagnosed with post-traumatic stress disorder in Veterans Administration. Am J Geriatr Psychiatry. 2008;16(10):804–12. [PubMed: 18827226]
53.
Mohamed S, Rosenheck RA. Pharmacotherapy of PTSD in the U.S. Department of Veterans Affairs: diagnostic-and symptom-guided drug selection. J Clin Psychiatry. 2008;69(6):959–65. [PubMed: 18588361]
54.
Harpaz-Rotem I, Rosenheck RA, Mohamed S, et al. Pharmacologic treatment of post-traumatic stress disorder among privately insured Americans. Psychiatr Serv. 2008;59(10):1184–90. [PubMed: 18832505]
55.
Mellman TA, Clark RE, Peacock WJ. Prescribing patterns for patients with post-traumatic stress disorder. Psychiatr Serv. 2003;54(12):1618–21. [PubMed: 14645801]
56.
Rosenheck R, Leslie D, Sernyak M. From clinical trials to real-world practice: use of atypical antipsychotic medication nationally in the Department of Veterans Affairs. Med Care. 2001;39(3):302–8. [PubMed: 11242324]
57.
Leslie DL, Mohamed S, Rosenheck RA. Off-label use of antipsychotic medications in the department of Veterans Affairs health care system. Psychiatr Serv. 2009;60(9):1175–81. [PubMed: 19723731]
58.
Philip NS, Mello K, Carpenter LL, et al. Patterns of quetiapine use in psychiatric inpatients: An examination of off-label use. Annals of Clinical Psychiatry. 2008;20(1):15–20. [PubMed: 18297582]
59.
Morrato EH, Dodd S, Oderda G, et al. Prevalence, utilization patterns, and predictors of antipsychotic polypharmacy: experience in a multistate Medicaid population, 1998-2003. Clin Ther. 2007;29(1):183–95. [PubMed: 17379060]
60.
Atik L, Erdogan A, Karaahmet E, et al. Antipsychotic prescriptions in a university hospital outpatient population in Turkey: a retrospective database analysis, 2005-2006. Prog Neuropsychopharmacol Biol Psychiatry. 2008;32(4):968–74. [PubMed: 18243462]
61.
Botvinik L, Ng C, Schweitzer I. Audit of antipsychotic prescribing in a private psychiatric hospital. Australas Psychiatry. 2004;12(3):227–33. [PubMed: 15715780]
62.
Doey T, Handelman K, Seabrook JA, et al. Survey of atypical antipsychotic prescribing by Canadian child psychiatrists and developmental pediatricians for patients aged under 18 years. Can J Psychiatry. 2007;52(6):363–8. [PubMed: 17696022]
63.
Harrison-Woolrych M, Garcia-Quiroga J, Ashton J, et al. Safety and usage of atypical antipsychotic medicines in children: a nationwide prospective cohort study. Drug Saf. 2007;30(7):569–79. [PubMed: 17604408]
64.
Taylor M, Shajahan P, Lawrie SM. Comparing the use and discontinuation of antipsychotics in clinical practice: An observational study. Journal of Clinical Psychiatry. 2008;69(2):240–5. [PubMed: 18363452]
65.
Aras S, Varol Tas F, Unlu G. Medication prescribing practices in a child and adolescent psychiatry outpatient clinic. Child Care Health Dev. 2007;33(4):482–90. [PubMed: 17584405]
66.
Fourrier A, Gasquet I, Allicar MP, et al. Patterns of neuroleptic drug prescription: a national cross-sectional survey of a random sample of French psychiatrists. British Journal of Clinical Pharmacology. 2000;49(1):80–6. [PMC free article: PMC2014886] [PubMed: 10606841]
67.
Schneeweiss S, Setoguchi S, Brookhart A, et al. Risk of death associated with the use of conventional versus atypical antipsychotic drugs among elderly patients. CMAJ. 2007;176(5):627–32. [PMC free article: PMC1800321] [PubMed: 17325327]
68.
Gill SS, Bronskill SE, Normand SLT, et al. Antipsychotic Drug Use and Mortality in Older Adults with Dementia. Ann Intern Med. 2007;146(11):775–86. [PubMed: 17548409]
69.
Alessi-Severini S, Biscontri RG, Collins DM, et al. Utilization and costs of antipsychotic agents: A Canadian population-based study, 1996-2006. Psychiatric Services. 2008;59(5):547–53. [PubMed: 18451015]
70.
Wittmann M, Hausner H, Hajak G, et al. Antipsychotic Treatment of Dementia After Publication of New Risks. Psychiatr Prax. 2009 [PubMed: 19724997]
71.
Nobili A, Pasina L, Trevisan S, et al. Use and misuse of antipsychotic drugs in patients with dementia in Alzheimer special care units. International Clinical Psychopharmacology. 2009;24(2):97–104. [PubMed: 21456106]
72.
Shah SM, Carey IM, Harris T, et al. Antipsychotic prescribing to older people living in care homes and the community in England and Wales. Int J Geriatr Psychiatry. 2010 [PubMed: 20878663]
73.
Gowers S, Claxton M, Rowlands L, et al. Drug prescribing in child and adolescent eating disorder services. Child and Adolescent Mental Health S2- Child Psychology & Psychiatry Review. 2010;15(1):18–22.
74.
Robinson M, Rowett D, Leverton A, et al. Changes in utilisation of anticholinergic drugs after initiation of cholinesterase inhibitors. Pharmacoepidemiol Drug Saf. 2009;18(8):659–64. [PubMed: 19548222]
75.
Chen H, Reeves JH, Fincham JE, et al. Off-label use of antidepressant, anticonvulsant, and antipsychotic medications among Georgia medicaid enrollees in 2001. J Clin Psychiatry. 2006;67(6):972–82. [PubMed: 16848658]
76.
Patel NC, Crismon ML, Shafer A. Diagnoses and antipsychotic treatment among youths in a public mental health system. Ann Pharmacother. 2006;40(2):205–11. [PubMed: 16434563]
77.
Armenteros JL, Lewis JE, Davalos M. Risperidone augmentation for treatment-resistant aggression in attention-deficit/hyperactivity disorder: a placebo-controlled pilot study. J Am Acad Child Adolesc Psychiatry. 2007;46(5):558–65. [PubMed: 17450046]
78.
Correia Filho AG, Bodanese R, Silva TL, et al. Comparison of risperidone and methylphenidate for reducing ADHD symptoms in children and adolescents with moderate mental retardation. J Am Acad Child Adolesc Psychiatry. 2005;44(8):748–55. [PubMed: 16034276]
79.
Tramontina S, Zeni CP, Ketzer CR, et al. Aripiprazole in children and adolescents with bipolar disorder comorbid with attention-deficit/hyperactivity disorder: a pilot randomized clinical trial. J Clin Psychiatry. 2009;70(5):756–64. [PubMed: 19389329]
80.
Zeni CP, Tramontina S, Ketzer CR, et al. Methylphenidate Combined with Aripiprazole in Children and Adolescents with Bipolar Disorder and Attention-Deficit/Hyperactivity Disorder: A Randomized Crossover Trial. Journal of Child and Adolescent Psychopharmacology. 2009;19(5):553–61. [PubMed: 19877980]
81.
Ipser JC, Carey P, Dhansay Y, et al. Pharmacotherapy augmentation strategies in treatment-resistant anxiety disorders. Cochrane Database Syst Rev. 2006;(4):CD005473. [PubMed: 17054260]
82.
Depping AM, Komossa K, Kissling W, et al. Second-generation antipsychotics for anxiety disorders. Cochrane Database Syst Rev. 2010;12:CD008120. [PubMed: 21154392]
83.
Barnett SD, Kramer ML, Casat CD, et al. Efficacy of olanzapine in social anxiety disorder: a pilot study. J Psychopharmacol. 2002;16(4):365–8. [PubMed: 12503837]
84.
Pollack MH, Simon NM, Zalta AK, et al. Olanzapine augmentation of fluoxetine for refractory generalized anxiety disorder: a placebo controlled study. Biol Psychiatry. 2006;59(3):211–5. [PubMed: 16139813]
85.
Simon NM, Connor KM, LeBeau RT, et al. Quetiapine augmentation of paroxetine CR for the treatment of refractory generalized anxiety disorder: preliminary findings. Psychopharmacology (Berl) 2008;197(4):675–81. [PubMed: 18246327]
86.
McIntyre A, Gendron A. Quetiapine adjunct to selective serotonin reuptake inhibitors or venlafaxine in patients with major depression, comorbid anxiety, and residual depressive symptoms: a randomized, placebo-controlled pilot study. Depress Anxiety. 2007;24(7):487–94. [PubMed: 17177199]
87.
Merideth C, Cutler A, Neijber A, et al. Efficacy and tolerability of extended release quetiapine fumarate monotherapy in the treatment of GAD. European Neuropsychopharmacology. 2008;18(Supplement 4):S499–S500.
88.
Bandelow B, Chouinard G, Bobes J, et al. Extended-release quetiapine fumarate (quetiapine XR): a once-daily monotherapy effective in generalized anxiety disorder. Data from a randomized, double-blind, placebo- and active-controlled study. Int J Neuropsychopharmacol. 2009:1–16. [PubMed: 19691907]
89.
Vaishnavi S, Alamy S, Zhang W, et al. Quetiapine as monotherapy for social anxiety disorder: a placebo-controlled study. Prog Neuropsychopharmacol Biol Psychiatry. 2007;31(7):1464–9. [PubMed: 17698275]
90.
Altamura AC, Serati M, Buoli M, et al. Augmentative quetiapine in partial/nonresponders with generalized anxiety disorder: a randomized, placebo-controlled study. Int Clin Psychopharmacol. 2011 [PubMed: 21403524]
91.
Khan A, Atkinson S, Mezhebovsky I, et al. Efficacy and safety of once-daily extended release quetiapine fumarate (quetiapine XR) as an adjunct therapy in patients with treatment non-responsive generalized anxiety disorder (GAD). 49th Annual New Clinical Drug Evaluation Unit Meeting; June 29 -July 2 2009; Poster.
92.
Hirschfeld RM, Weisler RH, Raines SR, et al. Quetiapine in the treatment of anxiety in patients with bipolar I or II depression: a secondary analysis from a randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2006;67(3):355–62. [PubMed: 16649820]
93.
Katzman MA, Brawman-Mintzer O, Reyes EB, et al. Extended release quetiapine fumarate (quetiapine XR) monotherapy as maintenance treatment for generalized anxiety disorder: a long-term, randomized, placebo-controlled trial. Int Clin Psychopharmacol. 2011;26(1):11–24. [PubMed: 20881846]
94.
Joyce M, Khan A, Eggens I, et al. Efficacy and safety of extended release quetiapine fumarate (quetiapine XR) monotherapy in patients with generalized anxiety disorder (GAD). Poster presented at the 161st annual meeting of the American Psychiatric Association; May 3-8, 2008.
95.
Donahue CB, Kushner MG, Thuras PD, et al. Effect of quetiapine vs. placebo on response to two virtual public speaking exposures in individuals with social phobia. J Anxiety Disord. 2009;23(3):362–8. [PubMed: 19157776]
96.
Prosser JM, Yard S, Steele A, et al. A comparison of low-dose risperidone to paroxetine in the treatment of panic attacks: a randomized, single-blind study. BMC Psychiatry. 2009;9:25. [PMC free article: PMC2696444] [PubMed: 19470174]
97.
Sheehan DV, McElroy SL, Harnett-Sheehan K, et al. Randomized, placebo-controlled trial of risperidone for acute treatment of bipolar anxiety. J Affect Disord. 2009;115(3):376–85. [PubMed: 19042026]
98.
Brawman-Mintzer O, Knapp RG, Nietert PJ. Adjunctive risperidone in generalized anxiety disorder: a double-blind, placebo-controlled study. J Clin Psychiatry. 2005;66(10):1321–5. [PubMed: 16259547]
99.
Pandina GJ, Canuso CM, Turkoz I, et al. Adjunctive risperidone in the treatment of generalized anxiety disorder: a double-blind, prospective, placebo-controlled, randomized trial. Psychopharmacol Bull. 2007;40(3):41–57. [PubMed: 18007568]
100.
Lohoff FW, Etemad B, Mandos LA, et al. Ziprasidone treatment of refractory generalized anxiety disorder: a placebo-controlled, double-blind study. J Clin Psychopharmacol. 2010;30(2):185–9. [PubMed: 20520293]
101.
Ballard C, Waite J. The effectiveness of atypical antipsychotics for the treatment of aggression and psychosis in Alzheimer's disease. Cochrane Database Syst Rev. 2006;(1):CD003476. [PubMed: 16437455]
102.
Schneider LS, Dagerman K, Insel PS. Efficacy and adverse effects of atypical antipsychotics for dementia: meta-analysis of randomized, placebo-controlled trials. Am J Geriatr Psychiatry. 2006;14(3):191–210. [PubMed: 16505124]
103.
De Deyn PP, Katz IR, Brodaty H, et al. Management of agitation, aggression, and psychosis associated with dementia: A pooled analysis including three randomized, placebo-controlled double-blind trials in nursing home residents treated with risperidone. Clin Neurol Neurosurg. 2005 Oct;107(6):497–508. [PubMed: 15922506]
104.
Yury CA, Fisher JE. Meta-Analysis of the Effectiveness of Atypical Antipsychotics for the Treatment of Behavioural Problems in Persons with Dementia. Psychotherapy and Psychosomatics. 2007;76(4):213–8. [PubMed: 17570959]
105.
DeDeyn PP, J DV, Mintzer JE, et al. Aripiprazole in dementia of the Alzheimer's type. 16th Annual Meeting of the American Association for Geriatric Psychiatry; 2003; Honolulu, Hawaii. 2003.
106.
Streim JE, McQuade RD, Stock E, et al. Aripiprazole treatment of institutionalized patients with psychosis of alszheimer's dementia. Poster presented at: Annual Meeting of the American Association of Geriatric Psychiatry; Feb 21-24, 2004.
107.
Mintzer JE, Tune LE, Breder CD, et al. Aripiprazole for the Treatment of Psychoses in Institutionalized Patients With Alzheimer Dementia: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Assessment of Three Fixed Doses. American Journal of Geriatric Psychiatry. 2007;15(11):918–31. [PubMed: 17974864]
108.
Streim JE, P AP, Breder CD, Swanink R, Marcus R, McQuade R, Carson WH. A randomized, double-blind, placebo-controlled study of aripiprazole for the treatment of psychosis in nursing home patients with Alzheimer disease. Am J Geriatr Psychiatry. 2008;16(7):537–50. [PubMed: 18591574]
109.
Rappaport SA, Marcus RN, Manos G, et al. A randomized, double-blind, placebo-controlled tolerability study of intramuscular aripiprazole in acutely agitated patients with Alzheimer's, vascular, or mixed dementia. J Am Med Dir Assoc. 2009;10(1):21–7. [PubMed: 19111849]
110.
Street JS, Clark WS, Gannon KS, et al. Olanzapine treatment of psychotic and behavioral symptoms in patients with Alzheimer disease in nursing care facilities: a double-blind, randomized, placebo-controlled trial. The HGEU Study Group. Arch Gen Psychiatry. 2000;57(10):968–76. [PubMed: 11015815]
111.
De Deyn PP, Carrasco MM, Deberdt W, et al. Olanzapine versus placebo in the treatment of psychosis with or without associated behavioral disturbances in patients with Alzheimer's disease. Int J Geriatr Psychiatry. 2004;19(2):115–26. [PubMed: 14758577]
112.
Sanger Todd M, Clark W, Scott Street, et al. Reduction of psychotic symptoms by olanzapine in patients with possible lewy body dementia. 155th Annual Meeting of the American Psychiatric Association; 2002 May 18-23rd; Philadelphia, PA, USA. 2002.
113.
Howanitz EW I. Olanzapine versus placebo in the treatment of behavioral disturbances associated with vascular dementia. 14th Annual Meeting of the American Association for Geriatric Psychiatry; 2001 23rd-26th February; San Francisco, CA, USA. 2001.
114.
Satterlee WG, Reams SG, Burns PR, et al. A clinical update on olanzapine treatment in schizophrenia and in elderly Alzheimer's disease patients. Psychopharmacol Bull. 1995;31:534.
115.
Herz LR, V L, Frankenburg F, Colon S, Kittur S. A 6-week, double-blind comparison of olanzapine, risperidone, and placebo for behavioral disturbances in Alzheimer's disease (abstract) J Clin Psychiatry. 2002;(63):1065.
116.
Deberdt WG, Dysken MW, Rappaport SA, et al. Comparison of olanzapine and risperidone in the treatment of psychosis and associated behavioral disturbances in patients with dementia. Am J Geriatr Psychiatry. 2005;13(8):722–30. [PubMed: 16085789]
117.
Street JS, Kinon F, Stauffer V. Olanzapine in dementia. In: Tran P, editor. Olanzapine (Zyprexa): A Novel Antipsychotic. Philadelphia, PA: Lippincott Wiliams & Wilkins; 2000. pp. 416–26.
118.
Kennedy J, D W, Siegal A, Micca J, Degenhardt E, Ahl J, Meyers A, Kaiser C, Baker RW. Olanzapine does not enhance cognition in non-agitated and non-psychotic patients with mild to moderate Alzheimer's dementia. Int J Geriatr Psychiatry. 2005;20(11):1020–7. [PubMed: 16250069]
119.
Sultzer DL, Davis SM, Tariot PN, et al. Clinical Symptom Responses to Atypical Antipsychotic Medications in Alzheimer's Disease: Phase 1 Outcomes From the CATIE-AD Effectiveness Trial. Am J Psychiatry. 2008;165(7):844–54. [PMC free article: PMC2714365] [PubMed: 18519523]
120.
Tariot PS, Katz L, Mintzer I, Street J. Quetiapine in nursing home residents with alzheimer's dementia and psychosis (poster). Annual Meeting of the American Association of Geriatric Psychiatry; 2002 February 24-27; Orlando, FL. 2002.
121.
Ballard C, ML M, Juszczak E, Douglas S, Swann A, Thomas A, O'Brien J, Everratt A, Sadler S, Maddison C, Lee L, Bannister C, Elvish R, Jacoby R. Quetiapine and rivastigmine and cognitive decline in Alzheimer's disease: randomised double blind placebo controlled trial. BMJ. 2005;330(7496):874. [PMC free article: PMC556156] [PubMed: 15722369]
122.
Zhong KX, Tariot PN, Mintzer J, et al. Quetiapine to Treat Agitation in Dementia: A Randomized, Double-Blind,Placebo-Controlled Study. Current Alzheimer Research. 2007;4(1):81–93. [PubMed: 17316169]
123.
Paleacu D, B Y, Mirecky I, Mazeh D. Quetiapine treatment for behavioural and psychological symptoms of dementia in Alzheimer's disease patients: A 6-week, double-blind, placebo-controlled study. International Journal of Geriatric Psychiatry. 2008;23(4):393–400. [PubMed: 17879256]
124.
Tariot PN, Schneider L, Katz IR, et al. Quetiapine treatment of psychosis associated with dementia: a double-blind, randomized, placebo-controlled clinical trial. Am J Geriatr Psychiatry. 2006;14(9):767–76. [PubMed: 16905684]
125.
De Deyn PP, Rabheru K, Rasmussen A, et al. A randomized trial of risperidone, placebo, and haloperidol for behavioral symptoms of dementia. Neurology. 1999;53(5):946–55. [PubMed: 10496251]
126.
Brodaty H, Ames D, Snowdon J, et al. A randomized placebo-controlled trial of risperidone for the treatment of aggression, agitation, and psychosis of dementia. J Clin Psychiatry. 2003;64(2):134–43. [PubMed: 12633121]
127.
Katz IR, Jeste DV, Mintzer JE, et al. Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia: a randomized, double-blind trial. Risperidone Study Group. J Clin Psychiatry. 1999;60(2):107–15. [PubMed: 10084637]
128.
Naber D, G Andrew, Schreiner Andreas. Efficacy and safety of risperidone in the treatment of elderly patients suffering from organic brain disease (organic brain syndrome): results from a double-blind, randomized, placebo-controlled clinical trial. Psychopharmacology. 2007;191(4):1027–9. [PubMed: 17333131]
129.
Mintzer J, Greenspan A, Caers I, et al. Risperidone in the Treatment of Psychosis of Alzheimer Disease: Results From a Prospective Clinical Trial. Am J Geriatr Psychiatry. March. 2006;14(3):280–91. [PubMed: 16505133]
130.
Gareri P, C A, Lacava R, Seminara G, Marigliano N, Loiacono A, De Sarro G. Comparison of the efficacy of new and conventional antipsychotic drugs in the treatment of behavioral and psychological symptoms of dementia (BPSD) Arch Gerontol Geriatr Suppl. 2004;(9):207–15. [PubMed: 15207416]
131.
Street JS, T GD, Tohen M, et al. Olanzapine for psychotic conditions in the elderly. Psychiatric Annals. 2000;30:191–6.
132.
Moretti R, T P, Antonello RM, Cattaruzza T, Cazzato G. Olanzapine as a possible treatment of behavioral symptoms in vascular dementia: risks of cerebrovascular events. A controlled, open-label study. J Neurol. 2005;252(10):1186–93. [PubMed: 15809822]
133.
Savaskan E, S C, Schroder C, Cajochen C, Muller-Spahn F, Wirz-Justice A. Treatment of behavioural, cognitive and circadian rest-activity cycle disturbances in Alzheimer's disease: haloperidol vs. quetiapine. Int J Neuropsychopharmacol. 2006;9(5):507–16. [PubMed: 16316485]
134.
Suh GH, Greenspan AJ, Choi SK. Comparative efficacy of risperidone versus haloperidol on behavioural and psychological symptoms of dementia: Comment. International Journal of Geriatric Psychiatry. 2007;22(5):494–5. [PubMed: 17471597]
135.
Pollock BG, Mulsant BH, Rosen J, et al. A double-blind comparison of citalopram and risperidone for the treatment of behavioral and psychotic symptoms associated with dementia. The American Journal of Geriatric Psychiatry. 2007;15(11):942–52. [PubMed: 17846102]
136.
Verhey FRJ, Verkaaik M, Lousberg R. Olanzapine versus Haloperidol in the Treatment of Agitation in Elderly Patients with Dementia: Results of a Randomized Controlled Double-Blind Trial. Dementia and Geriatric Cognitive Disorders. 2006;21(1):1–8. [PubMed: 16244481]
137.
Holmes C, W D, Dean C, Clare C, El-Okl M, Hensford C, Moghul S. Risperidone and rivastigmine and agitated behaviour in severe Alzheimer's disease: a randomised double blind placebo controlled study. Int J Geriatr Psychiatry. 2007;22(4):380–1. [PubMed: 17380475]
138.
Mowla A, Pani A. Comparison of topiramate and risperidone for the treatment of behavioral disturbances of patients with Alzheimer disease: a double-blind, randomized clinical trial. J Clin Psychopharmacol. 2010;30(1):40–3. [PubMed: 20075646]
139.
van Reekum R, C D, Conn D, Herrmann N, Eryavec G, Cohen T, Ostrander L. A randomized, placebo-controlled trial of the discontinuation of long-term antipsychotics in dementia. Int Psychogeriatr. 2002;14(2):197–210. [PubMed: 12243210]
140.
Ballard CG, T A, Fossey J, Lee L, Jacoby R, Lana MM, Bannister C, McShane R, Swann A, Juszczak E, O'Brien JT. A 3-month, randomized, placebo-controlled, neuroleptic discontinuation study in 100 people with dementia: the neuropsychiatric inventory median cutoff is a predictor of clinical outcome. J Clin Psychiatry. 2004;65(1):114–9. [PubMed: 14744180]
141.
Mulsant BH, G GM, Bossie CA, et al. Correlates of anticholinergic activity in patients with demntia and psychosis treated with risperidone or olanzapine. J Clin Psychiatry. 2004;65:1708–14. [PubMed: 15641877]
142.
Rainer M, H M, Pfolz H, Struhal C, Wick W. Quetiapine versus risperidone in elderly patients with behavioural and psychological symptoms of dementia: Efficacy, safety and cognitive function. European Psychiatry. 2007;22(6):395–403. [PubMed: 17482432]
143.
Ruths S, S Jørund, Nygaard Harald A, Aarsland Dag. Stopping antipsychotic drug therapy in demented nursing home patients: A randomized, placebo-controlled study--The Bergen District Nursing Home Study (BEDNURS) International Journal of Geriatric Psychiatry. 2008;23(9):889–95. [PubMed: 18306150]
144.
Ballard C, L Marisa Margallo, Theodoulou Megan, Douglas Simon, McShane Rupert, Jacoby Robin, Kossakowski Katja, Yu Ly-Mee, Juszczak Edmund. on behalf of the Investigators, Dart Ad. A Randomised, Blinded, Placebo-Controlled Trial in Dementia Patients Continuing or Stopping Neuroleptics (The DART-AD Trial) PLoS Med. 2008;5(4):e76. [PMC free article: PMC2276521] [PubMed: 18384230]
145.
Cummings JL, Mega M, Gray K, et al. The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology. 1994;44(12):2308–14. [PubMed: 7991117]
146.
Breder C, S R, Marcus R, et al. Dose-ranging study of ariprprazole in patients with Alzheimer's dementia. 9th International Conference on Alzheimer's Desease and Related Disorders; 2004; Philadelphia, PA. 2004.
147.
Streim JE, Breder C, Swanink R, et al. Flexible dose aripiprazole in psychosis of alzheimer's dementia. American Psychiatric Association Annual Meeting; 2004; New York, NY. 2004.
148.
Schneider LS, Tariot PN, Dagerman KS, et al. Effectiveness of Atypical Antipsychotic Drugs in Patients with Alzheimer's Disease. N Engl J Med. 2006;355(15):1525–38. [PubMed: 17035647]
149.
Zhong X, T P, Minkwitz MC, Devine NA, Mintzer J. Quetiapine for the treatment of agitation in elderly institutionalized patients with dementia: a randomized, double-blind trial. 56th Institute in Psychiatric Services (IPS); 2004 October 6-10; Atlanta GA. 2004.
150.
Brodaty H, Ames D, Snowdon J, et al. Risperidone for psychosis of Alzheimer's disease and mixed dementia: results of a double-blind, placebo-controlled trial. Int J Geriatr Psychiatry. 2005;20(12):1153–7. [PubMed: 16315159]
151.
Papakostas GI, Shelton RC, Smith J, et al. Augmentation of antidepressants with atypical antipsychotic medications for treatment-resistant major depressive disorder: a meta-analysis. J Clin Psychiatry. 2007;68(6):826–31. [PubMed: 17592905]
152.
Nelson JC, Papakostas GI. Atypical antipsychotic augmentation in major depressive disorder: a meta-analysis of placebo-controlled randomized trials. Am J Psychiatry. 2009;166(9):980–91. [PubMed: 19687129]
153.
Kim D, Berman R, Marcus R, et al. Aripiprazole as adjunctive therapy in major depressive disorder wiih and withoui chronic features (CN138-139) (poster no, 283]; 160th Annual Meeting of the American Psychiatric Association; 2007 May 19-24.
154.
Marcus RN, McQuade RD, Carson WH, et al. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: A second multicenter, randomized, double-blind, placebo-controlled study. Journal of Clinical Psychopharmacology. 2008;28(2):156–65. [PubMed: 18344725]
155.
Berman RM, Marcus RN, Swanink R, et al. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2007;68(6):843–53. [PubMed: 17592907]
156.
Berman RM, Fava M, Thase ME, et al. Aripiprazole augmentation in major depressive disorder: a double-blind, placebo-controlled study in patients with inadequate response to antidepressants. CNS Spectr. 2009;14(4):197–206. [PubMed: 19407731]
157.
Zheng L, Jing C, Xia L, et al. Efficacy and tolerability of quetiapine combined with antidepressants in patients with treatment-resistant depression [poster]. Presented at the 20th European College of Neuropsychopharmacology Congress; Oct 13-17, 2007.
158.
Chaput Y, Magnan A, Gendron A. The co-administration of quetiapine or placebo to cognitive-behavior therapy in treatment refractory depression: a preliminary trial. BMC Psychiatry. 2008;8:73. [PMC free article: PMC2553785] [PubMed: 18752690]
159.
El-Khalili N, Joyce M, Atkinson S, et al. Extended-release quetiapine fumarate (quetiapine XR) as adjunctive therapy in major depressive disorder (MDD) in patients with an inadequate response to ongoing antidepressant treatment: a multicentre, randomized, double-blind, placebo-controlled study. Int J Neuropsychopharmacol. 2010;13(7):917–32. [PubMed: 20175941]
160.
Garakani A, Martinez JM, Marcus S, et al. A randomized, double-blind, and placebo-controlled trial of quetiapine augmentation of fluoxetine in major depressive disorder. Int Clin Psychopharmacol. 2008;23(5):269–75. [PubMed: 18703936]
161.
Mattingly G, Ilivicky H, Canale J, et al. Quetiapine combination for treatment-resistant depression [poster NR250]. Presented at the American Psychiatric Association 159th annual meeting; May 20-25, 2006.
162.
Bauer M, Pretorius HW, Constant EL, et al. Extended-release quetiapine as adjunct to an antidepressant in patients with major depressive disorder: results of a randomized, placebo-controlled, double-blind study. J Clin Psychiatry. 2009;70(4):540–9. [PubMed: 19358791]
163.
Nemeroff CB, Gharabawi G, Canuso C, et al. Augmentation with risperidone in chronic resistant depression: a double-blind, placebo-controlled maintenance trial. Neuropsychopharmacology. 2004;29(S159)
164.
Reeves H, Batra S, May RS, et al. Efficacy of risperidone augmentation to antidepressants in the management of suicidality in major depressive disorder: a randomized, double-blind, placebo-controlled pilot study. J Clin Psychiatry. 2008;69(8):1228–336. [PubMed: 18681749]
165.
Keitner GI, Garlow SJ, Ryan CE, et al. A randomized, placebo-controlled trial of risperidone augmentation for patients with difficult-to-treat unipolar, non-psychotic major depression. Journal of Psychiatric Research. 2009;43(3):205–14. [PMC free article: PMC3685867] [PubMed: 18586273]
166.
Mahmoud RA, Pandina GJ, Turkoz I, et al. Risperidone for Treatment-Refractory Major Depressive Disorder: A Randomized Trial. Ann Intern Med. 2007;147(9):593–602. [PubMed: 17975181]
167.
Gharabawi G, Canuso C, Pandina G, et al. Risperdone treatment of resistant depression: A double-blind randomized trial. Neuropsychopharmacology. 2006;31(Suppl 1):S228.
168.
AstraZeneca. A Multi-Centre, Double-Blind, Randomised, Parallel Group, Placebo-Controlled and Active Controlled Phase III Study of the Efficacy and Safety of Quetiapine Fumarate Extended Release (SEROQUEL XR™) as Mono-Therapy in the Treatment of Adult Patients with Major Depressive Disorder (AMBER STUDY) Nov 20, 2007. www.astrazenecaclinicaltrials.com/_mshost800325/content/clinicaltrials/resources/pdf/8579603 ClinicalTrials.gov ID NCT00351169. Study code: D1448COOO04.
169.
AstraZeneca. A Multi-Center, Double-Blind, Randomized, Parallel-Group, Placebo-Controlled Phase III Study of the Efficacy and Safety of Quetiapine Fumarate Extended-Release (Seroquel XRTM) as Mono-Therapy in the Treatment of Elderly Patients with Major Depressive Disorder (SAPPHIRE STUDY) Apr 22, 2008. www.astrazenecaclinicaltrials.com/_mshost800325/content/clinicaltrials/resources/pdf/8579646 ClinicalTrials.gov ID NCT00388973. Study code: D1448C00014.
170.
Bortnick B, El-Khalili N, Banov M, et al. Efficacy and tolerability of extended release quetiapine fumarate (quetiapine XR) monotherapy in major depressive disorder: a placebo-controlled, randomized study. J Affect Disord. 2011;128(1-2):83–94. [PubMed: 20691481]
171.
Cutler AJ, Montgomery SA, Feifel D, et al. Extended release quetiapine fumarate monotherapy in major depressive disorder: a placebo- and duloxetine-controlled study. J Clin Psychiatry. 2009;70(4):526–39. [PubMed: 19358790]
172.
Weisler R, Joyce M, McGill L, et al. Extended release quetiapine fumarate monotherapy for major depressive disorder: results of a double-blind, randomized, placebo-controlled study. CNS Spectr. 2009;14(6):299–313. [PubMed: 19668121]
173.
AstraZeneca. A Multicenter, Double-blind, Randomized-withdrawal, Parallel-group, Placebo-controlled Phase III Study of the Efficacy and Safety of Quetiapine Fumarate Extended Release (SEROQUEL XR™) as Monotherapy in the Maintenance Treatment of Patients with Major Depressive Disorder Following an Open-Label Stabilization Period (AMETHYST STUDY) Jan 29, 2008. www.astrazenecaclinicaltrials.com/_mshost800325/content/clinicaltrials/resources/pdf/8579609 ClinicalTrials.gov ID NCT00278941. Study code: D1448C00005.
174.
Thase ME, Corya SA, Osuntokun O, et al. A randomized, double-blind comparison of olanzapine/fluoxetine combination, olanzapine, and fluoxetine in treatment-resistant major depressive disorder. J Clin Psychiatry. 2007;68(2):224–36. [PubMed: 17335320]
175.
Doree JP, Des Rosiers J, Lew V, et al. Quetiapine augmentation of treatment-resistant depression: a comparison with lithium. Curr Med Res Opin. 2007;23(2):333–41. [PubMed: 17288688]
176.
Dunner DL, Amsterdam JD, Shelton RC, et al. Efficacy and tolerability of adjunctive ziprasidone in treatment-resistant depression: A randomized, open-label, pilot study. Journal of Clinical Psychiatry. 2007;68(7):1071–7. [PubMed: 17685744]
177.
Hussain MZ, Waheed W, Hussain S, et al. A comparison of unipolar depression treatment using antidepressants alone versus using antidepressants in combination with quetiapine. European Neuropsychopharmacology. 2005;15(Supplement 3):S453–S4.
178.
Rothschild AJ, Williamson DJ, Tohen MF, et al. A double-blind, randomized study of olanzapine and olanzapine/fluoxetine combination for major depression with psychotic features. J Clin Psychopharmacol. 2004;24(4):365–73. [PubMed: 15232326]
179.
McKnight RF, Park RJ. Atypical antipsychotics and anorexia nervosa: a review. Eur Eat Disord Rev. 2010;18(1):10–21. [PubMed: 20054875]
180.
Bissada H, Tasca GA, Barber AM, et al. Olanzapine in the Treatment of Low Body Weight and Obsessive Thinking in Women With Anorexia Nervosa: A Randomized, Double-Blind, Placebo-Controlled Trial. Am J Psychiatry. 2008;165(10):1281–8. [PubMed: 18558642]
181.
Mondraty N, Birmingham CL, Touyz S, et al. Randomized controlled trial of olanzapine in the treatment of cognitions in anorexia nervosa. Australasian Psychiatry. 2005;13(1):72–5. [PubMed: 15777417]
182.
Brambilla F, Garcia CS, Fassino S, et al. Olanzapine therapy in anorexia nervosa: psychobiological effects. Int Clin Psychopharmacol. 2007;22(4):197–204. [PubMed: 17519642]
183.
Brambilla F, Monteleone P, Maj M. Olanzapine-induced weight gain in anorexia nervosa: involvement of leptin and ghrelin secretion? Psychoneuroendocrinology. 2007;32(4):402–6. [PubMed: 17395395]
184.
Gaskill JA, Treat TA, McCabe EB, et al. Does olanzapine affect the rate of weight gane among inpatients with eating disorders? Int J Eat Disord Review. 2001;12:1–2.
185.
Court A, Mulder C, Kerr M, et al. Investigating the effectiveness, safety and tolerability of quetiapine in the treatment of anorexia nervosa in young people: a pilot study. J Psychiatr Res. 2010;44(15):1027–34. [PubMed: 20447652]
186.
Sharpley AL, Attenburrow ME, Hafizi S, et al. Olanzapine increases slow wave sleep and sleep continuity in SSRI-resistant depressed patients. J Clin Psychiatry. 2005;66(4):450–4. [PubMed: 15816787]
187.
Estivill E, de la Fuente V, Segarra F, et al. [The use of olanzapine in sleep disorders An open trial with nine patients] Rev Neurol. 2004;38(9):829–31. [PubMed: 15152350]
188.
Wiegand MH, Landry F, Bruckner T, et al. Quetiapine in primary insomnia: a pilot study. Psychopharmacology (Berl) 2008;196(2):337–8. [PubMed: 17922110]
189.
Teran A, Majadas S, Galan J. Quetiapine in the treatment of sleep disturbances associated with addictive conditions: a retrospective study. Subst Use Misuse. 2008;43(14):2169–71. [PubMed: 19085442]
190.
Pasquini M, Speca A, Biondi M. Quetiapine for tamoxifen-induced insomnia in women with breast cancer. Psychosomatics. 2009;50(2):159–61. [PubMed: 19377025]
191.
Juri C, Chana P, Tapia J, et al. Quetiapine for insomnia in Parkinson disease: results from an open-label trial. Clin Neuropharmacol. 2005;28(4):185–7. [PubMed: 16062098]
192.
Bloch MH, LW A, Kelmendi B, Coric V, Bracken MB, Leckman JF. A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder. Mol Psychiatry. 2006;11(7):622–32. [PubMed: 16585942]
193.
Skapinakis P, Papatheodorou T, Mavreas V. Antipsychotic augmentation of serotonergic antidepressants in treatment-resistant obsessive-compulsive disorder: a meta-analysis of the randomized controlled trials. Eur Neuropsychopharmacol. 2007;17(2):79–93. [PubMed: 16904298]
194.
Fineberg NA, Stein DJ, Premkumar P, et al. Adjunctive quetiapine for serotonin reuptake inhibitor-resistant obsessive-compulsive disorder: a meta-analysis of randomized controlled treatment trials. Int Clin Psychopharmacol. 2006;21(6):337–43. [PubMed: 17012980]
195.
Maina G, Pessina E, Albert U, et al. 8-week, single-blind, randomized trial comparing risperidone versus olanzapine augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder. European Neuropsychopharmacology. 2008;18(5):364–72. [PubMed: 18280710]
196.
de Geus F, Denys D, Westenberg HG. Effects of quetiapine on cognitive functioning in obsessive-compulsive disorder. Int Clin Psychopharmacol. 2007;22(2):77–84. [PubMed: 17293707]
197.
Kordon A, Wahl K, Koch N, et al. Quetiapine addition to serotonin reuptake inhibitors in patients with severe obsessive-compulsive disorder: a double-blind, randomized, placebo-controlled study. J Clin Psychopharmacol. 2008;28(5):550–4. [PubMed: 18794652]
198.
Matsunaga H, Nagata T, Hayashida K, et al. A long-term trial of the effectiveness and safety of atypical antipsychotic agents in augmenting SSRI-refractory obsessive-compulsive disorder. J Clin Psychiatry. 2009;70(6):863–8. [PubMed: 19422759]
199.
Vulink NC, Denys D, Fluitman SB, et al. Quetiapine augments the effect of citalopram in non-refractory obsessive-compulsive disorder: a randomized, double-blind, placebo-controlled study of 76 patients. J Clin Psychiatry. 2009;70(7):1001–8. [PubMed: 19497245]
200.
Diniz J, Shavitt R, Pereira C, et al. Quetiapine versus clomipramine in the augmentation of selective serotonin reuptake inhibitors for the treatment of obsessive-compulsive disorder: a randomized, open-label trial. J Psychopharmacol. 2010 March;24(3):297–307. [PubMed: 19164490]
201.
Denys D, Vulink N, Fluitman S, et al. Quetiapine addition to serotonin reuptake inhibitors in non-refractory obsessive compulsive disorder [abstract] Neuropsychopharmacol. 2006;31(suppl 1):S104. Abstract 85.
202.
Vulink NCC, Fluitman S, Meinardi JCM, et al. Double-blind, randomized, placebo-controlled addition of quetiapine in non-refractory OCD patients. European Neuropsychopharmacology. 2007;17(Supplement 1):S86–S7.
203.
Denys D, d G F, van Megen HJ, Westenberg HG. A double-blind, randomized, placebo-controlled trial of quetiapine addition in patients with obsessive-compulsive disorder refractory to serotonin reuptake inhibitors. J Clin Psychiatry. 2004;65(8):1040–8. [PubMed: 15323587]
204.
Atmaca M, K M, Tezcan E, Gecici O. Quetiapine augmentation in patients with treatment resistant obsessive-compulsive disorder: a single-blind, placebo-controlled study. Int Clin Psychopharmacol. 2002;17(3):115–9. [PubMed: 11981352]
205.
Carey PD, Vythilingum B, Seedat S, et al. Quetiapine augmentation of SRIs in treatment refractory obsessive-compulsive disorder: a double-blind, randomised, placebo-controlled study. BMC Psychiatry. 2005;5(1):5. [PMC free article: PMC547907] [PubMed: 15667657]
206.
Fineberg NA, Sivakumaran T, Roberts A, et al. Adding quetiapine to SRI in treatment-resistant obsessive-compulsive disorder: a randomized controlled treatment study. Int Clin Psychopharmacol. 2005;20(4):223–6. [PubMed: 15933483]
207.
Bystritsky A, A DL, Rosen RM, Vapnik T, Gorbis E, Maidment KM, Saxena S. Augmentation of serotonin reuptake inhibitors in refractory obsessive-compulsive disorder using adjunctive olanzapine: a placebo-controlled trial. J Clin Psychiatry. 2004;65(4):565–8. [PubMed: 15119922]
208.
Shapira NA, Ward HE, Mandoki M, et al. A double-blind, placebo-controlled trial of olanzapine addition in fluoxetine-refractory obsessive-compulsive disorder. Biol Psychiatry. 2004;55(5):553–5. [PubMed: 15023585]
209.
Erzegovesi S, G E, Siliprandi F, Bellodi L. Low-dose risperidone augmentation of fluvoxamine treatment in obsessive-compulsive disorder: a double-blind, placebo-controlled study. Eur Neuropsychopharmacol. 2005;15(1):69–74. [PubMed: 15572275]
210.
Hollander E, R N, Sood BE, Pallanti S. Risperidone augmentation in treatment-resistant obsessive-compulsive disorder: a double-blind, placebo-controlled study. Int J Neuropsychopharmacol. 2003;6(4):397–401. [PubMed: 14604454]
211.
McDougle CJ, E CN, Pelton GH, Wasylink S, Price LH. A double-blind, placebo-controlled study of risperidone addition in serotonin reuptake inhibitor-refractory obsessive-compulsive disorder. Arch Gen Psychiatry. 2000;57(8):794–801. [PubMed: 10920469]
212.
Savas HA, Yumru M, Özen ME. Quetiapine and Ziprasidone as Adjuncts in Treatment-Resistant Obsessive-Compulsive Disorder: A Retrospective Comparative Study. Clinical Drug Investigation. 2008;28(7):439. [PubMed: 18544004]
213.
Ingenhoven T, Lafay P, Rinne T, et al. Effectiveness of pharmacotherapy for severe personality disorders: meta-analyses of randomized controlled trials. J Clin Psychiatry. 2010;71(1):14–25. [PubMed: 19778496]
214.
Zanarini MC, Frankenburg FR. Olanzapine treatment of female borderline personality disorder patients: a double-blind, placebo-controlled pilot study. J Clin Psychiatry. 2001;62(11):849–54. [PubMed: 11775043]
215.
Soler J, Pascual JC, Campins J, et al. Double-blind, placebo-controlled study of dialectical behavior therapy plus olanzapine for borderline personality disorder. Am J Psychiatry. 2005;162(6):1221–4. [PubMed: 15930077]
216.
Bogenschutz MP, George Nurnberg H. Olanzapine versus placebo in the treatment of borderline personality disorder. J Clin Psychiatry. 2004;65(1):104–9. [PubMed: 14744178]
217.
Koenigsberg HW, Reynolds D, Goodman M, et al. Risperidone in the treatment of schizotypal personality disorder. J Clin Psychiatry. 2003;64(6):628–34. [PubMed: 12823075]
218.
Nickel MK, Muehlbacher M, Nickel C, et al. Aripiprazole in the treatment of patients with borderline personality disorder: a double-blind, placebo-controlled study. Am J Psychiatry. 2006;163(5):833–8. [PubMed: 16648324]
219.
Nickel M, Loew T, Gil F. Aripiprazole in treatment of borderline patients, part II: an 18-month follow-up. Psychopharmacology. 2007;191(4):1023–6. [PubMed: 17318503]
220.
Zanarini MC, Schulz SC, Detke HC, et al. A dose comparison of olanzapine for the treatment of borderline personality disorder: A 12-week randomized double-blind placebo-controlled study. European Psychiatry. 2007;22(Supplement 1):S172–S3.
221.
van den Broek PJA, Penterman B, Hummelen JW, et al. The effect of quetiapine on psychotic-like symptoms in borderline personality disorder. A placebo-controlled trial. European Neuropsychopharmacology. 2008;18(Supplement 4):S425–S6.
222.
Pascual JC, Soler J, Puigdemont D, et al. Ziprasidone in the treatment of borderline personality disorder: a double-blind, placebo-controlled, randomized study. J Clin Psychiatry. 2008;69(4):603–8. [PubMed: 18251623]
223.
Schulz SC, Zanarini MC, Bateman A, et al. Olanzapine for the treatment of borderline personality disorder: variable dose 12-week randomised double-blind placebo-controlled study. Br J Psychiatry. 2008;193(6):485–92. [PubMed: 19043153]
224.
Linehan MM, McDavid JD, Brown MZ, et al. Olanzapine plus dialectical behavior therapy for women with high irritability who meet criteria for borderline personality disorder: A double-blind, placebo-controlled pilot study. Journal of Clinical Psychiatry. 2008;69(6):999–1005. [PubMed: 18466045]
225.
Shafti SS, Shahveisi B. Olanzapine versus haloperidol in the management of borderline personality disorder: a randomized double-blind trial. J Clin Psychopharmacol. 2010;30(1):44–7. [PubMed: 20075647]
226.
Bozzatello P, Bellino S, Rinaldi C, et al. Paliperidone in the treatment of borderline personality disorder: a pilot study of efficacy and tolerability. European Neuropsychopharmacology. 2009;19(Supplement 3):S513–S.
227.
McClure MM, Koenigsberg HW, Reynolds D, et al. The effects of risperidone on the cognitive performance of individuals with schizotypal personality disorder. J Clin Psychopharmacol. 2009;29(4):396–8. [PMC free article: PMC4176874] [PubMed: 19593186]
228.
Pae CU, Lim HK, Peindl K, et al. The atypical antipsychotics olanzapine and risperidone in the treatment of post-traumatic stress disorder: a meta-analysis of randomized, double-blind, placebo-controlled clinical trials. International Clinical Psychopharmacology. 2008;23(1):1–8. [PubMed: 18090502]
229.
Ahearn EP, Juergens T, Cordes T, et al. A review of atypical antipsychotic medications for post-traumatic stress disorder. Int Clin Psychopharmacol. 2011 [PubMed: 21597381]
230.
Bartzokis G, Lu PH, Turner J, et al. Adjunctive risperidone in the treatment of chronic combat-related post-traumatic stress disorder. Biol Psychiatry. 2004;57(5):474–9. [PubMed: 15737661]
231.
Reich DB, Winternitz S, Hennen J, et al. A preliminary study of risperidone in the treatment of post-traumatic stress disorder related to childhood abuse in women. J Clin Psychiatry. 2004;65(12):1601–6. [PubMed: 15641864]
232.
Monnelly EP, Ciraulo DA, Knapp C, et al. Low-dose risperidone as adjunctive therapy for irritable aggression in post-traumatic stress disorder. J Clin Psychopharmacol. 2003;23(2):193–6. [PubMed: 12640221]
233.
Padala PR, Madison J, Monnahan M, et al. Risperidone monotherapy for post-traumatic stress disorder related to sexual assault and domestic abuse in women. Int Clin Psychopharmacol. 2006;21(5):275–80. [PubMed: 16877898]
234.
Hamner MB, Faldowski RA, Ulmer HG, et al. Adjunctive risperidone treatment in post-traumatic stress disorder: a preliminary controlled trial of effects on comorbid psychotic symptoms. Int Clin Psychopharmacol. 2003;18(1):1–8. [PubMed: 12490768]
235.
Stein MB, Kline NA, Matloff JL. Adjunctive olanzapine for SSRI-resistant combat-related PTSD: a double-blind, placebo-controlled study. Am J Psychiatry. 2002;159(10):1777–9. [PubMed: 12359687]
236.
Butterfield MI, Becker ME, Connor KM, et al. Olanzapine in the treatment of post-traumatic stress disorder: a pilot study. Int Clin Psychopharmacol. 2001;16(4):197–203. [PubMed: 11459333]
237.
Rothbaum BO, Killeen TK, Davidson JR, et al. Placebo-controlled trial of risperidone augmentation for selective serotonin reuptake inhibitor-resistant civilian post-traumatic stress disorder. J Clin Psychiatry. 2008;69(4):520–5. [PubMed: 18278987]
238.
Hamner MB, Ulmer HG, Faldowski RA, et al. A randomized, controlled trial of risperidone for psychotic features in PTSD. Biological Psychiatry. 2000;47(8, Supplement 1):S158–S9.
239.
Hamner MB, Robert S, Canive J. Quetiapine monotherapy in chronic post-traumatic stress disorder: A randomized, double-blind, placebo-controlled trial [abstract] Euro Neuropsychopharmacol. 2009;19(suppl. 3):S591–S692. Abs P.4.a.011.
240.
Ozdemir A, Kocabasoglu N, Yargic I. NR646: Quetiapine/sertraline combination in PTSD. Presented at the 159th Annual Meeting of the American Psychiatric Association; 20-25 May 2006.
241.
Padala PR, Monnahan M, Ramaswamy S, et al. Risperidone in the treatment for post-traumatic stress disorder (PTSD) in women [poster], NCDEU. Boca Raton, FL: 2005.
242.
Rubio G, Martínez I, Recio A, et al. Risperidone versus Zuclopenthixol in the Treatment of Schizophrenia with Substance Abuse Comorbidity: A Long-term Randomized, Controlled, Crossover Study. European Journal of Psychiatry. 2006;20(3):133–46.
243.
Rubio G, Martinez I, Ponce G, et al. Long-acting injectable risperidone compared with zuclopenthixol in the treatment of schizophrenia with substance abuse comorbidity. Can J Psychiatry. 2006;51(8):531–9. [PubMed: 16933590]
244.
Sayers SL, Campbell EC, Kondrich J, et al. Cocaine abuse in schizophrenic patients treated with olanzapine versus haloperidol. J Nerv Ment Dis. 2005;193(6):379–86. [PubMed: 15920378]
245.
Smelson DA, Ziedonis D, Williams J, et al. The efficacy of olanzapine for decreasing cue-elicited craving in individuals with schizophrenia and cocaine dependence: a preliminary report. J Clin Psychopharmacol. 2006;26(1):9–12. [PubMed: 16415698]
246.
Tsuang J, Marder SR, Han A, et al. Olanzapine treatment for patients with schizophrenia and cocaine abuse. J Clin Psychiatry. 2002;63(12):1180–1. [PubMed: 12530415]
247.
Akerele E, Levin FR. Comparison of olanzapine to risperidone in substance-abusing individuals with schizophrenia. Am J Addict. 2007;16(4):260–8. [PubMed: 17661193]
248.
Gerra G, Di Petta G, D'Amore A, et al. Combination of olanzapine with opioid-agonists in the treatment of heroin-addicted patients affected by comorbid schizophrenia spectrum disorders. Clin Neuropharmacol. 2007;30(3):127–35. [PubMed: 17545747]
249.
Green AI, Tohen MF, Hamer RM, et al. First episode schizophrenia-related psychosis and substance use disorders: acute response to olanzapine and haloperidol. Schizophr Res. 2004;66(2-3):125–35. [PubMed: 15061244]
250.
Nejtek VA, Avila M, Chen LA, et al. Do atypical antipsychotics effectively treat co-occurring bipolar disorder and stimulant dependence? A randomized, double-blind trial. Journal of Clinical Psychiatry. 2008;69(8):1257–66. [PubMed: 18681757]
251.
Martinotti G, Di Nicola M, Di Giannantonio M, et al. Aripiprazole in the treatment of patients with alcohol dependence: a double-blind, comparison trial vs. naltrexone. J Psychopharmacol. 2009;23(2):123–9. [PubMed: 18515460]
252.
Anton RF, Kranzler H, Breder C, et al. A randomized, multicenter, double-blind, placebo-controlled study of the efficacy and safety of aripiprazole for the treatment of alcohol dependence. J Clin Psychopharmacol. 2008;28(1):5–12. [PubMed: 18204334]
253.
Voronin K, Randall P, Myrick H, et al. Aripiprazole effects on alcohol consumption and subjective reports in a clinical laboratory paradigm--possible influence of self-control. Alcohol Clin Exp Res. 2008;32(11):1954–61. [PMC free article: PMC2588475] [PubMed: 18782344]
254.
Anton R, Breder C, Han J, et al. Aripiprazole in the treatment of alcohol dependence: results from a multisite study. Neuropsychopharmacology. 2006;31(suppl 1):S200. Abstract.
255.
Hutchison KE, Wooden A, Swift RM, et al. Olanzapine reduces craving for alcohol: a DRD4 VNTR polymorphism by pharmacotherapy interaction. Neuropsychopharmacology. 2003;28(10):1882–8. [PubMed: 12888781]
256.
Guardia J, Segura L, Gonzalvo B, et al. A double-blind, placebo-controlled study of olanzapine in the treatment of alcohol-dependence disorder. Alcohol Clin Exp Res. 2004;28(5):736–45. [PubMed: 15166648]
257.
Hutchison KE, Ray L, Sandman E, et al. The effect of olanzapine on craving and alcohol consumption. Neuropsychopharmacology. 2006;31(6):1310–7. [PubMed: 16237394]
258.
Hutchison KE, Swift R, Rohsenow DJ, et al. Olanzapine reduces urge to drink after drinking cues and a priming dose of alcohol. Psychopharmacology. 2001;155(1):27–34. [PubMed: 11374333]
259.
Kampman KM, Pettinati HM, Lynch KG, et al. A double-blind, placebo-controlled pilot trial of quetiapine for the treatment of Type A and Type B alcoholism. J Clin Psychopharmacol. 2007;27(4):344–51. [PMC free article: PMC3193934] [PubMed: 17632217]
260.
Guardia J, Roncero C, Galan J, et al. A double-blind, placebo-controlled, randomized pilot study comparing quetiapine with placebo, associated to naltrexone, in the treatment of alcohol-dependent patients. Addict Behav. 2011;36(3):265–9. [PubMed: 21146937]
261.
Lile JA, Stoops WW, Hays LR, et al. The safety, tolerability, and subject-rated effects of acute intranasal cocaine administration during aripiprazole maintenance II: increased aripipirazole dose and maintenance period. Am J Drug Alcohol Abuse. 2008;34(6):721–9. [PMC free article: PMC2713051] [PubMed: 18855244]
262.
Stoops WW, Lile JA, Lofwall MR, et al. The safety, tolerability, and subject-rated effects of acute intranasal cocaine administration during aripiprazole maintenance. Am J Drug Alcohol Abuse. 2007;33(6):769–76. [PubMed: 17994473]
263.
Hamilton JD, Nguyen QX, Gerber RM, et al. Olanzapine in cocaine dependence: a double-blind, placebo-controlled trial. Am J Addict. 2009;18(1):48–52. [PubMed: 19219665]
264.
Kampman KM, Pettinati H, Lynch KG, et al. A pilot trial of olanzapine for the treatment of cocaine dependence. Drug Alcohol Depend. 2003;70(3):265–73. [PubMed: 12757964]
265.
Reid MS, Casadonte P, Baker S, et al. A placebo-controlled screening trial of olanzapine, valproate, and coenzyme Q10/L-carnitine for the treatment of cocaine dependence. Addiction. 2005;100 1:43–57. [PubMed: 15730349]
266.
Grabowski J, Rhoades H, Silverman P, et al. Risperidone for the treatment of cocaine dependence: randomized, double-blind trial. J Clin Psychopharmacol. 2000;20(3):305–10. [PubMed: 10831016]
267.
Smelson DA, Roy A, Roy M. Risperidone and neuropsychological test performance in cocaine-withdrawn patients. Can J Psychiatry. 1997;42(4):431. [PubMed: 9161774]
268.
Levin FR, McDowell D, Evans SM, et al. Pergolide mesylate for cocaine abuse: a controlled preliminary trial. Am J Addict. 1999;8(2):120–7. [PubMed: 10365192]
269.
Loebl T, Angarita GA, Pachas GN, et al. A randomized, double-blind, placebo-controlled trial of long-acting risperidone in cocaine-dependent men. Journal of Clinical Psychiatry. 2008;69(3):480–6. [PubMed: 18294021]
270.
Smelson DA, Williams J, Ziedonis D, et al. A double-blind placebo-controlled pilot study of risperidone for decreasing cue-elicited craving in recently withdrawn cocaine dependent patients. J Subst Abuse Treat. 2004;27(1):45–9. [PubMed: 15223093]
271.
Tiihonen J, Kuoppasalmi K, Fohr J, et al. A comparison of aripiprazole, methylphenidate, and placebo for amphetamine dependence. Am J Psychiatry. 2007;164(1):160–2. [PubMed: 17202560]
272.
Newton TF, Reid MS, De La Garza R, et al. Evaluation of subjective effects of aripiprazole and methamphetamine in methamphetamine-dependent volunteers. Int J Neuropsychopharmacol. 2008;11(8):1037–45. [PMC free article: PMC2782728] [PubMed: 18664303]
273.
Gerra G, Di Petta G, D'Amore A, et al. Effects of olanzapine on aggressiveness in heroin dependent patients. Prog Neuropsychopharmacol Biol Psychiatry. 2006;30(7):1291–8. [PubMed: 16766110]
274.
Grabowski J, Rhoades H, Stotts A, et al. Agonist-like or antagonist-like treatment for cocaine dependence with methadone for heroin dependence: two double-blind randomized clinical trials. Neuropsychopharmacology. 2004;29(5):969–81. [PubMed: 15039761]
275.
Amato L, M S, Pani PP, Davoli M. Antipsychotic medications for cocaine dependence. Cochrane Database Syst Rev. 2007;(3):CD006306. [PubMed: 17636840]
276.
Budman C, Coffey BJ, Shechter R, et al. Aripiprazole in children and adolescents with Tourette disorder with and without explosive outbursts. J Child Adolesc Psychopharmacol. 2008;18(5):509–15. [PubMed: 18928415]
277.
Yoo HK, Choi SH, Park S, et al. An open-label study of the efficacy and tolerability of aripiprazole for children and adolescents with tic disorders. J Clin Psychiatry. 2007;68(7):1088–93. [PubMed: 17685747]
278.
Alexopoulos GS, Canuso CM, Gharabawi GM, et al. Placebo-controlled study of relapse prevention with risperidone augmentation in older patients with resistant depression. The American Journal of Geriatric Psychiatry. 2008;16(1):21–30. [PMC free article: PMC2788739] [PubMed: 17928573]
279.
Vigen CL, Mack WJ, Keefe RS, et al. Cognitive Effects of Atypical Antipsychotic Medications in Patients With Alzheimer's Disease: Outcomes From CATIE-AD. Am J Psychiatry. 2011 [PMC free article: PMC3310182] [PubMed: 21572163]
280.
Kales HC, Valenstein M, Kim HM, et al. Mortality Risk in Patients With Dementia Treated With Antipsychotics Versus Other Psychiatric Medications. Am J Psychiatry. 2007;164(10):1568–76. [PubMed: 17898349]
281.
Rossom RC, Rector TS, Lederle FA, et al. Are all commonly prescribed antipsychotics associated with greater mortality in elderly male veterans with dementia? J Am Geriatr Soc. 2010;58(6):1027–34. [PubMed: 20487081]
282.
Liperoti R, Onder G, Landi F, et al. All-cause mortality associated with atypical and conventional antipsychotics among nursing home residents with dementia: a retrospective cohort study. J Clin Psychiatry. 2009;70(10):1340–7. [PMC free article: PMC3775351] [PubMed: 19906339]
283.
Huybrechts KF, Rothman KJ, Silliman RA, et al. Risk of death and hospital admission for major medical events after initiation of psychotropic medications in older adults admitted to nursing homes. CMAJ. 2011;183(7):E411–9. [PMC free article: PMC3080558] [PubMed: 21444611]
284.
Sacchetti E, Turrina C, Cesana B, et al. Timing of stroke in elderly people exposed to typical and atypical antipsychotics: a replication cohort study after the paper of Kleijer, et al. J Psychopharmacol. 2010;24(7):1131–2. [PubMed: 19304861]
285.
Pratt NL, Roughead EE, Ramsay E, et al. Risk of hospitalization for stroke associated with antipsychotic use in the elderly: a self-controlled case series. Drugs Aging. 2010;27(11):885–93. [PubMed: 20964462]
286.
Parker C, Coupland C, Hippisley-Cox J. Antipsychotic drugs and risk of venous thromboembolism: nested case-control study. BMJ. 2010;341:c4245. [PubMed: 20858909]
287.
Barnett MJ, Wehring H, Perry PJ. Comparison of risk of cerebrovascular events in an elderly VA population with dementia between antipsychotic and nonantipsychotic users. J Clin Psychopharmacol. 2007;27(6):595–601. [PubMed: 18004126]
288.
Lipkovich I, A Jonna, Nichols Russell, Hardy Thomas, Poole Hoffmann Vicki. Weight Changes During Treatment With Olanzapine in Older Adult Patients With Dementia and Behavioral Disturbances. J Geriatr Psychiatry Neurol. 2007;20(2):107–14. [PubMed: 17548781]
289.
Micca JL, Hoffmann VP, Lipkovich I, et al. Retrospective Analysis of Diabetes Risk in Elderly Patients With Dementia in Olanzapine Clinical Trials. American Journal of Geriatric Psychiatry. 2006;14(1):62–70. [PubMed: 16407583]
290.
Rochon PA, Normand SL, Gomes T, et al. Antipsychotic Therapy and Short-term Serious Events in Older Adults With Dementia. Arch Intern Med. 2008;168(10):1090–6. [PubMed: 18504337]
291.
Olfson M, M Steven C, Corey-Lisle Patricia, Tuomari AV, Hines Patricia, L'Italien Gilbert J. Hyperlipidemia Following Treatment With Antipsychotic Medications. Am J Psychiatry. 2006;163(10):1821–5. [PubMed: 17012695]
292.
Ray WA, Chung CP, Murray KT, et al. Atypical Antipsychotic Drugs and the Risk of Sudden Cardiac Death. N Engl J Med. 2009;360(3):225–35. [PMC free article: PMC2713724] [PubMed: 19144938]
293.
De Deyn PP, De Smedt G. Long-term safety and efficacy of risperidone in the treatment of behavioural disturbances in elderly patients with dementia. 11th ECNP Congress; 1998; Paris, France. 1998.
294.
Chan WC, Lam LC, Choy CN, et al. A double-blind randomised comparison of risperidone and haloperidol in the treatment of behavioural and psychological symptoms in Chinese dementia patients. Int J Geriatr Psychiatry. 2001;16(12):1156–62. [PubMed: 11748775]
295.
Fontaine CS, Hynan LS, Koch K, et al. A double-blind comparison of olanzapine versus risperidone in the acute treatment of dementia-related behavioral disturbances in extended care facilities. J Clin Psychiatry. 2003;64(6):726–30. [PubMed: 12823090]
296.
Mintzer Jea. Efficacy and safety of a flexible dose of risperidone versus placebo in the treatment of psychosis of Alzheimer's disease. Poster presented at the 4th Annual Meeting of the ICGP; 2004; Basal, Switzerland. 2004.
297.
Clark WS, Street JS, Feldman PD, et al. The effects of olanzapine in reducing the emergence of psychosis among nursing home patients with Alzheimer's disease. J Clin Psychiatry. 2001;62(1):34–40. [PubMed: 11235926]
298.
Mintzer J, Faison W, Street JS, et al. Olanzapine in the treatment of anxiety symptoms due to Alzheimer's disease: a post hoc analysis. Int J Geriatr Psychiatry. 2001;16 1:S71–7. [PubMed: 11748790]
299.
De Deyn PP, Jeste D, Mintzer J. Aripiprazole in demential of the Alzheimer's type. 16th annual meeting of the American Association for Geriatric Psychiatry; 2003; Honolulu, HI. 2003.
300.
Li X, May RS, Tolbert LC, et al. Risperidone and haloperidol augmentation of serotonin reuptake inhibitors in refractory obsessive-compulsive disorder: a crossover study. J Clin Psychiatry. 2005;66(6):736–43. [PubMed: 15960567]
301.
Arbaizar B, Dierssen-Sotos T, Gomez-Acebo I, et al. Aripiprazole in major depression and mania: meta-analyses of randomized placebo-controlled trials. Gen Hosp Psychiatry. 2009;31(5):478–83. [PubMed: 19703642]
302.
Shelton RC, Tollefson GD, Tohen M, et al. A novel augmentation strategy for treating resistant major depression. Am J Psychiatry. 2001;158(1):131–4. [PubMed: 11136647]
303.
Shelton RC, W DJ, Corya SA, Sanger TM, Van Campen LE, Case M, Briggs SD, Tollefson GD. Olanzapine/fluoxetine combination for treatment-resistant depression: a controlled study of SSRI and nortriptyline resistance. J Clin Psychiatry. 2005;66(10):1289–97. [PubMed: 16259543]
304.
Corya SA, Williamson D, Sanger TM, et al. A randomized, double-blind comparison of olanzapine/fluoxetine combination, olanzapine, fluoxetine and venlafaxine in treatment-resistant depression. Depression and Anxiety. 2006;23:364–72. [PubMed: 16710853]
305.
El-Khalili N, Joyce M, Atkinson S, et al. Adjunctive extended-release quetiapine fumarate (quetiapine XR) in patients with major depressive disorder and inadequate antidepressant response [poster]. Presented at: the 161st Annual Meeting of the American Psychiatric Association; May 3-8, 2008.
306.
Earley W, McIntyre A, Wang G, et al. Double-blind study of the efficacy and tolerability of extended release quetiapine fumarate (quetiapine XR) monotherapy in patients with major depressive disorder (MDD) [poster]. Presented at: the 8th International Forum on Mood and Anxiety Disorders; November 12-14, 2008.
307.
Tassniyom K, Paholpak S, Tassniyom S, et al. Quetiapine for primary insomnia: a double blind, randomized controlled trial. J Med Assoc Thai. 2010;93(6):729–34. [PubMed: 20572379]

Views

  • PubReader
  • Print View
  • Cite this Page
  • PDF version of this title (11M)

Related information

  • PMC
    PubMed Central citations
  • PubMed
    Links to PubMed

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...